Literature DB >> 31079293

Chronic Mild Gut Inflammation Accelerates Brain Neuropathology and Motor Dysfunction in α-Synuclein Mutant Mice.

Yuki Kishimoto1, Wandi Zhu2, Waki Hosoda3, Jyoti M Sen4,5, Mark P Mattson6,7.   

Abstract

Emerging findings suggest that Parkinson's disease (PD) pathology (α-synuclein accumulation) and neuronal dysfunction may occur first in peripheral neurons of the autonomic nervous system including the enteric branches of the vagus nerve. The risk of PD increases greatly in people over the age of 65, a period of life in which chronic inflammation is common in many organ systems including the gut. Here we report that chronic mild focal intestinal inflammation accelerates the age of disease onset in α-synuclein mutant PD mice. Wild-type and PD mice treated with 0.5% dextran sodium sulfate (DSS) in their drinking water for 12 weeks beginning at 3 months of age exhibited histological and biochemical features of mild gut inflammation. The age of onset of motor dysfunction, evaluated using a rotarod test, gait analysis, and grip strength measurements, was significantly earlier in DSS-treated PD mice compared to control PD mice. Levels of the dopaminergic neuron marker tyrosine hydroxylase in the striatum and numbers of dopaminergic neurons in the substantia nigra were reduced in PD mice with gut inflammation. Levels of total and phosphorylated α-synuclein were elevated in enteric and brain neurons in DSS-treated PD mice, suggesting that mild gut inflammation accelerates α-synuclein pathology. Markers of inflammation in the colon and brain, but not in the blood, were elevated in DSS-treated PD mice, consistent with retrograde transneuronal propagation of α-synuclein pathology and neuroinflammation from the gut to the brain. Our findings suggest that interventions that reduce gut inflammation may prove beneficial in the prevention and treatment of PD.

Entities:  

Keywords:  Alpha-synuclein; Dopaminergic neurons; Enteric neurons; Neuroinflammation; Parkinson’s disease

Year:  2019        PMID: 31079293      PMCID: PMC6701950          DOI: 10.1007/s12017-019-08539-5

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  44 in total

1.  Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson's disease?

Authors:  R J Phillips; G C Walter; S L Wilder; E A Baronowsky; T L Powley
Journal:  Neuroscience       Date:  2008-03-18       Impact factor: 3.590

Review 2.  When does Parkinson disease start?

Authors:  Rodolfo Savica; Walter A Rocca; J Eric Ahlskog
Journal:  Arch Neurol       Date:  2010-07

3.  Where does parkinson disease pathology begin in the brain?

Authors:  Kelly Del Tredici; Udo Rüb; Rob A I De Vos; Jürgen R E Bohl; Heiko Braak
Journal:  J Neuropathol Exp Neurol       Date:  2002-05       Impact factor: 3.685

Review 4.  Genetic animal models of Parkinson's disease.

Authors:  Ted M Dawson; Han Seok Ko; Valina L Dawson
Journal:  Neuron       Date:  2010-06-10       Impact factor: 17.173

5.  Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration.

Authors:  Sreeganga Chandra; Gilbert Gallardo; Rafael Fernández-Chacón; Oliver M Schlüter; Thomas C Südhof
Journal:  Cell       Date:  2005-11-04       Impact factor: 41.582

Review 6.  Beneficial effects of intermittent fasting and caloric restriction on the cardiovascular and cerebrovascular systems.

Authors:  Mark P Mattson; Ruiqian Wan
Journal:  J Nutr Biochem       Date:  2005-03       Impact factor: 6.048

Review 7.  Neuroinflammation in Parkinson's disease: is there sufficient evidence for mechanism-based interventional therapy?

Authors:  Malú G Tansey; Tamy C Frank-Cannon; Melissa K McCoy; Jae Kyung Lee; Terina N Martinez; Fiona E McAlpine; Kelly A Ruhn; Thi A Tran
Journal:  Front Biosci       Date:  2008-01-01

8.  Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy.

Authors:  Chee Yeun Chung; James B Koprich; Hasan Siddiqi; Ole Isacson
Journal:  J Neurosci       Date:  2009-03-18       Impact factor: 6.167

9.  Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease.

Authors:  Hui-Ming Gao; Feng Zhang; Hui Zhou; Wayneho Kam; Belinda Wilson; Jau-Shyong Hong
Journal:  Environ Health Perspect       Date:  2011-01-18       Impact factor: 9.031

10.  Striatal neuroinflammation promotes Parkinsonism in rats.

Authors:  Dong-Young Choi; Mei Liu; Randy L Hunter; Wayne A Cass; Jignesh D Pandya; Patrick G Sullivan; Eun-Joo Shin; Hyoung-Chun Kim; Don M Gash; Guoying Bing
Journal:  PLoS One       Date:  2009-05-08       Impact factor: 3.240

View more
  27 in total

Review 1.  NAD+ in Brain Aging and Neurodegenerative Disorders.

Authors:  Sofie Lautrup; David A Sinclair; Mark P Mattson; Evandro F Fang
Journal:  Cell Metab       Date:  2019-10-01       Impact factor: 27.287

Review 2.  Inflammatory Animal Models of Parkinson's Disease.

Authors:  Juan García-Revilla; Antonio J Herrera; Rocío M de Pablos; José Luis Venero
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

Review 3.  The Pathological Mechanism Between the Intestine and Brain in the Early Stage of Parkinson's Disease.

Authors:  Runing Yang; Ge Gao; Hui Yang
Journal:  Front Aging Neurosci       Date:  2022-06-24       Impact factor: 5.702

Review 4.  T Lymphocytes in Parkinson's Disease.

Authors:  Elena Contaldi; Luca Magistrelli; Cristoforo Comi
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

Review 5.  Gut microbiome-mediated regulation of neuroinflammation.

Authors:  John W Bostick; Aubrey M Schonhoff; Sarkis K Mazmanian
Journal:  Curr Opin Immunol       Date:  2022-04-21       Impact factor: 7.268

Review 6.  Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?

Authors:  Alberto J Espay; Lorraine V Kalia; Ziv Gan-Or; Caroline H Williams-Gray; Philippe L Bedard; Steven M Rowe; Francesca Morgante; Alfonso Fasano; Benjamin Stecher; Marcelo A Kauffman; Matthew J Farrer; Chris S Coffey; Michael A Schwarzschild; Todd Sherer; Ronald B Postuma; Antonio P Strafella; Andrew B Singleton; Roger A Barker; Karl Kieburtz; C Warren Olanow; Andres Lozano; Jeffrey H Kordower; Jesse M Cedarbaum; Patrik Brundin; David G Standaert; Anthony E Lang
Journal:  Neurology       Date:  2020-02-26       Impact factor: 9.910

Review 7.  Neurodegenerative disorders and gut-brain interactions.

Authors:  Alpana Singh; Ted M Dawson; Subhash Kulkarni
Journal:  J Clin Invest       Date:  2021-07-01       Impact factor: 19.456

Review 8.  Emerging targets for the diagnosis of Parkinson's disease: examination of systemic biomarkers.

Authors:  Lara Cheslow; Adam E Snook; Scott A Waldman
Journal:  Biomark Med       Date:  2021-05-14       Impact factor: 2.498

Review 9.  Environmental triggers of Parkinson's disease - Implications of the Braak and dual-hit hypotheses.

Authors:  Honglei Chen; Keran Wang; Filip Scheperjans; Bryan Killinger
Journal:  Neurobiol Dis       Date:  2021-12-23       Impact factor: 7.046

10.  A gut bacterial amyloid promotes α-synuclein aggregation and motor impairment in mice.

Authors:  Collin Challis; Neha Jain; Timothy R Sampson; Anastasiya Moiseyenko; Mark S Ladinsky; Gauri G Shastri; Taren Thron; Brittany D Needham; Istvan Horvath; Justine W Debelius; Stefan Janssen; Rob Knight; Pernilla Wittung-Stafshede; Viviana Gradinaru; Matthew Chapman; Sarkis K Mazmanian
Journal:  Elife       Date:  2020-02-11       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.